Research Snappy
  • Market Research Forum
  • Investment Research
  • Consumer Research
  • More
    • Advertising Research
    • Healthcare Research
    • Data Analysis
    • Top Companies
    • Latest News
No Result
View All Result
Research Snappy
No Result
View All Result

La Jolla Pharmaceutical (NASDAQ:LJPC) Receives $7.50 Average PT from Analysts

researchsnappy by researchsnappy
January 5, 2020
in Healthcare Research
0
La Jolla Pharmaceutical (NASDAQ:LJPC) Downgraded by HC Wainwright to “Neutral”
399
SHARES
2.3k
VIEWS
Share on FacebookShare on Twitter

La Jolla Pharmaceutical logoLa Jolla Pharmaceutical (NASDAQ:LJPC) has been assigned an average recommendation of “Hold” from the nine research firms that are currently covering the company, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, five have issued a hold recommendation and three have given a buy recommendation to the company. The average twelve-month price target among brokerages that have updated their coverage on the stock in the last year is $7.50.

A number of equities research analysts have recently weighed in on LJPC shares. ValuEngine upgraded shares of La Jolla Pharmaceutical from a “hold” rating to a “buy” rating in a research note on Friday. HC Wainwright downgraded shares of La Jolla Pharmaceutical from a “buy” rating to a “neutral” rating in a research note on Tuesday, November 26th. SunTrust Banks downgraded shares of La Jolla Pharmaceutical from a “buy” rating to a “hold” rating in a research note on Monday, November 25th. Finally, BidaskClub downgraded shares of La Jolla Pharmaceutical from a “hold” rating to a “sell” rating in a research note on Friday, September 27th.

Shares of LJPC remained flat at $$3.89 during mid-day trading on Tuesday. 347,801 shares of the stock were exchanged, compared to its average volume of 981,053. The business’s fifty day moving average price is $3.95 and its 200 day moving average price is $7.70. La Jolla Pharmaceutical has a one year low of $2.30 and a one year high of $13.90. The company has a market cap of $105.64 million, a P/E ratio of -0.50 and a beta of 2.05.

La Jolla Pharmaceutical (NASDAQ:LJPC) last posted its quarterly earnings results on Tuesday, November 12th. The biopharmaceutical company reported ($1.08) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.05) by ($0.03). La Jolla Pharmaceutical had a negative net margin of 683.88% and a negative return on equity of 715.11%. The company had revenue of $5.71 million during the quarter, compared to analyst estimates of $6.96 million. As a group, equities analysts anticipate that La Jolla Pharmaceutical will post -4.43 EPS for the current year.

A number of hedge funds and other institutional investors have recently modified their holdings of LJPC. Sio Capital Management LLC bought a new position in La Jolla Pharmaceutical in the 2nd quarter valued at approximately $12,121,000. Boxer Capital LLC bought a new position in La Jolla Pharmaceutical in the 2nd quarter valued at approximately $5,319,000. SG Americas Securities LLC raised its holdings in La Jolla Pharmaceutical by 394.8% in the 3rd quarter. SG Americas Securities LLC now owns 375,986 shares of the biopharmaceutical company’s stock valued at $3,309,000 after buying an additional 299,995 shares during the last quarter. VHCP Management III LLC raised its holdings in La Jolla Pharmaceutical by 24.7% in the 2nd quarter. VHCP Management III LLC now owns 1,251,898 shares of the biopharmaceutical company’s stock valued at $11,580,000 after buying an additional 248,298 shares during the last quarter. Finally, Rock Springs Capital Management LP raised its holdings in La Jolla Pharmaceutical by 53.3% in the 2nd quarter. Rock Springs Capital Management LP now owns 425,000 shares of the biopharmaceutical company’s stock valued at $3,931,000 after buying an additional 147,764 shares during the last quarter. Institutional investors and hedge funds own 91.62% of the company’s stock.

La Jolla Pharmaceutical Company Profile

La Jolla Pharmaceutical Company, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for life-threatening diseases. The company offers GIAPREZA (angiotensin II), an injection for intravenous infusion indicated to increase blood pressure in adults with septic or other distributive shock.

Read More: Which market index is the best?

Analyst Recommendations for La Jolla Pharmaceutical (NASDAQ:LJPC)

Receive News & Ratings for La Jolla Pharmaceutical Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for La Jolla Pharmaceutical and related companies with MarketBeat.com’s FREE daily email newsletter.

Previous Post

What are the legal risks of using AI in recruiting

Next Post

Google’s AI venture fund leads USD 7 mln financing for Romanian tech startup

Next Post
Google’s AI venture fund leads USD 7 mln financing for Romanian tech startup

Google’s AI venture fund leads USD 7 mln financing for Romanian tech startup

Research Snappy

Category

  • Advertising Research
  • Consumer Research
  • Data Analysis
  • Healthcare Research
  • Investment Research
  • News

Pa. Republicans reconsider Pitt funding over fetal tissue research, college voucher program

Arthur Pharma Closes Series A Financing Round

YouTube and the Achilles Tendon: An Analysis of Internet Information Reliability and Content Quality

  • Privacy Policy
  • Terms of Use
  • Antispam
  • DMCA
  • Contact Us

© 2022 researchsnappy.com

No Result
View All Result
  • Market Research Forum
  • Investment Research
  • Consumer Research
  • More
    • Advertising Research
    • Healthcare Research
    • Data Analysis
    • Top Companies
    • Latest News

© 2022 researchsnappy.com